Schering AG has acquired Celera Genomics’ cathepsin S inhibitor small molecule drug program for the treatment of autoimmune diseases. The terms of the transaction include an upfront cash payment of $5 million, half of which is payable to Celera upon closing of the agreement. The remaining half will be payable upon the successful transfer of Celera’s cathepsin S inhibitor assets, which is expected to be completed within four months. If this program is successful, it may generate futur...